Oxford Cancer Analytics Ltd. | Ontario at the Biotech Showcase 2025

Profile

Oxford Cancer Analytics (OXcan) is creating a paradigm shift in early disease detection, monitoring, and treatment of lung cancer. OXcan’s multidisciplinary team invented a liquid biopsy blood test developed via cutting-edge proteomics and machine learning that can detect lung cancers early enough when they can still be cured. Fully integrated with existing clinical pathways for accelerated deployment and collaborating with 15+ leading centres of excellence across three continents, this blood test can be conducted in an affordable, minimally invasive, and routine manner in large populations with standard equipment in any diagnostics facility at 1/10th of the cost compared to conventional approaches.